{"id":2055,"date":"2020-06-04T16:04:56","date_gmt":"2020-06-04T14:04:56","guid":{"rendered":"https:\/\/www.arbios.org\/?p=2055"},"modified":"2020-06-04T16:07:35","modified_gmt":"2020-06-04T14:07:35","slug":"ans-biotech-launches-a-new-neuropathic-pain-model","status":"publish","type":"post","link":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/","title":{"rendered":"ANS Biotech launches a new iatrogenic neuropathic pain model."},"content":{"rendered":"<p>In France, the total number of new cancer cases is estimated at about 400,000 each year.<\/p>\n<p>Chemotherapy-induced peripheral neuropathy (CIPN) occurs frequently in patients treated with different anti-cancer agents, such as oxaliplatin (85%-95%).<\/p>\n<p>Oxaliplatin is a third-generation platinum-based chemotherapy drug widely used in the treatment of advanced metastatic colorectal cancer (45,000 new cases\/year in France) but its use is limited by a cumulative and chronic hematotoxicity, nephrotoxicity and neurotoxicity. The latter, particularly debilitating, is difficult to assess and treatments remain empirical and ineffective. Clinical signs include dysesthesia (pain caused by stimulus or contact) and paresthesia (tingling, burning) in the distal extremities, spontaneous pain and loss of sensation.<\/p>\n<p>The limitation of current iatrogenic pain treatments encourage companies like ANS Biotech to develop relevant preclinical models.<br \/>\nIn the particular case of oxaliplatin, chronic peripheral sensory neuropathy is induced by repeated injections of oxaliplatin (4 mg\/kg) twice a week during 3 consecutive weeks.<\/p>\n<p>Specialized in Services and R&amp;D in pharmacology of pain, ANS Biotech has developed a a model of hypersensitivity to cold induced by Oxaliplatin.<\/p>\n<p>This model enables exploring significant behavioural nociceptive signs and is consistent with clinical symptoms increasing progressively in duration and severity with repetition of treatment-cycles. It is useful to evaluate the antalgic effects of new compounds provided by its customers on oxaliplatin-induced chronic painful symptoms.<\/p>\n<p><span style=\"color: #008000;\">CONTACT<\/span><br \/>\n<span style=\"color: #008000;\">Biop\u00f4le Clermont-Limagne<\/span><br \/>\nFran\u00e7ois Caussade<br \/>\nPhone: +33 970 758 500<br \/>\nEmail: <a href=\"mailto:contact@ans-biotech.com\"><span style=\"color: #008000;\">contact@ans-biotech.com<\/span><\/a><br \/>\nWebsite: <a href=\"http:\/\/www.ans-biotech.com\">www.ans-biotech.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In France, the total number of new cancer cases is estimated at about 400,000 each year. Chemotherapy-induced peripheral neuropathy (CIPN) occurs frequently in patients treated with different anti-cancer agents, such as oxaliplatin (85%-95%). Oxaliplatin is a third-generation platinum-based chemotherapy drug widely used in the treatment of advanced metastatic colorectal cancer (45,000 new cases\/year in France) [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":2052,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2055","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ANS Biotech launches a new iatrogenic neuropathic pain model. - Arbios<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ANS Biotech launches a new iatrogenic neuropathic pain model. - Arbios\" \/>\n<meta property=\"og:description\" content=\"In France, the total number of new cancer cases is estimated at about 400,000 each year. Chemotherapy-induced peripheral neuropathy (CIPN) occurs frequently in patients treated with different anti-cancer agents, such as oxaliplatin (85%-95%). Oxaliplatin is a third-generation platinum-based chemotherapy drug widely used in the treatment of advanced metastatic colorectal cancer (45,000 new cases\/year in France) [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/\" \/>\n<meta property=\"og:site_name\" content=\"Arbios\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-04T14:04:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-04T14:07:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arbios.org\/wp-content\/uploads\/2020\/06\/mains.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"402\" \/>\n\t<meta property=\"og:image:height\" content=\"277\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"arbios\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"arbios\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/\"},\"author\":{\"name\":\"arbios\",\"@id\":\"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b\"},\"headline\":\"ANS Biotech launches a new iatrogenic neuropathic pain model.\",\"datePublished\":\"2020-06-04T14:04:56+00:00\",\"dateModified\":\"2020-06-04T14:07:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/\"},\"wordCount\":242,\"image\":{\"@id\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arbios.org\/wp-content\/uploads\/2020\/06\/mains.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/\",\"url\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/\",\"name\":\"ANS Biotech launches a new iatrogenic neuropathic pain model. - Arbios\",\"isPartOf\":{\"@id\":\"https:\/\/www.arbios.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arbios.org\/wp-content\/uploads\/2020\/06\/mains.jpg\",\"datePublished\":\"2020-06-04T14:04:56+00:00\",\"dateModified\":\"2020-06-04T14:07:35+00:00\",\"author\":{\"@id\":\"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#primaryimage\",\"url\":\"https:\/\/www.arbios.org\/wp-content\/uploads\/2020\/06\/mains.jpg\",\"contentUrl\":\"https:\/\/www.arbios.org\/wp-content\/uploads\/2020\/06\/mains.jpg\",\"width\":402,\"height\":277},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.arbios.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ANS Biotech launches a new iatrogenic neuropathic pain model.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arbios.org\/#website\",\"url\":\"https:\/\/www.arbios.org\/\",\"name\":\"Arbios\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arbios.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b\",\"name\":\"arbios\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arbios.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"caption\":\"arbios\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ANS Biotech launches a new iatrogenic neuropathic pain model. - Arbios","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/","og_locale":"en_US","og_type":"article","og_title":"ANS Biotech launches a new iatrogenic neuropathic pain model. - Arbios","og_description":"In France, the total number of new cancer cases is estimated at about 400,000 each year. Chemotherapy-induced peripheral neuropathy (CIPN) occurs frequently in patients treated with different anti-cancer agents, such as oxaliplatin (85%-95%). Oxaliplatin is a third-generation platinum-based chemotherapy drug widely used in the treatment of advanced metastatic colorectal cancer (45,000 new cases\/year in France) [&hellip;]","og_url":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/","og_site_name":"Arbios","article_published_time":"2020-06-04T14:04:56+00:00","article_modified_time":"2020-06-04T14:07:35+00:00","og_image":[{"width":402,"height":277,"url":"https:\/\/www.arbios.org\/wp-content\/uploads\/2020\/06\/mains.jpg","type":"image\/jpeg"}],"author":"arbios","twitter_card":"summary_large_image","twitter_misc":{"Written by":"arbios","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#article","isPartOf":{"@id":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/"},"author":{"name":"arbios","@id":"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b"},"headline":"ANS Biotech launches a new iatrogenic neuropathic pain model.","datePublished":"2020-06-04T14:04:56+00:00","dateModified":"2020-06-04T14:07:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/"},"wordCount":242,"image":{"@id":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arbios.org\/wp-content\/uploads\/2020\/06\/mains.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/","url":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/","name":"ANS Biotech launches a new iatrogenic neuropathic pain model. - Arbios","isPartOf":{"@id":"https:\/\/www.arbios.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#primaryimage"},"image":{"@id":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arbios.org\/wp-content\/uploads\/2020\/06\/mains.jpg","datePublished":"2020-06-04T14:04:56+00:00","dateModified":"2020-06-04T14:07:35+00:00","author":{"@id":"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b"},"breadcrumb":{"@id":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#primaryimage","url":"https:\/\/www.arbios.org\/wp-content\/uploads\/2020\/06\/mains.jpg","contentUrl":"https:\/\/www.arbios.org\/wp-content\/uploads\/2020\/06\/mains.jpg","width":402,"height":277},{"@type":"BreadcrumbList","@id":"https:\/\/www.arbios.org\/en\/ans-biotech-launches-a-new-neuropathic-pain-model\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.arbios.org\/en\/"},{"@type":"ListItem","position":2,"name":"ANS Biotech launches a new iatrogenic neuropathic pain model."}]},{"@type":"WebSite","@id":"https:\/\/www.arbios.org\/#website","url":"https:\/\/www.arbios.org\/","name":"Arbios","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arbios.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b","name":"arbios","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arbios.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","caption":"arbios"}}]}},"_links":{"self":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts\/2055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/comments?post=2055"}],"version-history":[{"count":4,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts\/2055\/revisions"}],"predecessor-version":[{"id":2059,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts\/2055\/revisions\/2059"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/media\/2052"}],"wp:attachment":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/media?parent=2055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}